Go Pro
→ Iran War Shock: What I Was Told In That Private Meeting (From Banyan Hill Publishing) (Ad)tc pixel

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Compare
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Ampio Pharmaceuticals, Inc. stock logo
AMPE
Ampio Pharmaceuticals
$0.18
$0.18
$0.00
▼
$0.64
$208K5.962,326 shsN/A
Carisma Therapeutics Inc. stock logo
CARM
Carisma Therapeutics
$0.00
-47.8%		$0.01
$0.00
▼
$0.56
$50K-9.0966,317 shs201 shs
Invitae Co. stock logo
NVTA
Invitae
$0.00
$0.00
$0.02
▼
$0.02
$80K1.5923.72 million shsN/A
Petros Pharmaceuticals, Inc. stock logo
PTPI
Petros Pharmaceuticals
$0.00
+22.9%		$0.00
$0.00
▼
$0.03
$134K1.88112,522 shs501,039 shs
7 Energy Stocks to Buy and Hold Forever Cover
7 Energy Stocks to Buy and Hold Forever

With the proliferation of data centers and electric vehicles, the electric grid will only get more strained. Download this report to learn how energy stocks can play a role in your portfolio as the global demand for energy continues to grow.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Ampio Pharmaceuticals, Inc. stock logo
AMPE
Ampio Pharmaceuticals
0.00%0.00%0.00%0.00%+6,681.48%
Carisma Therapeutics Inc. stock logo
CARM
Carisma Therapeutics
+4.55%+4.55%-45.24%+2,200.00%-99.04%
Invitae Co. stock logo
NVTA
Invitae
0.00%0.00%0.00%0.00%0.00%
Petros Pharmaceuticals, Inc. stock logo
PTPI
Petros Pharmaceuticals
-10.26%+2.94%-12.50%-42.62%-88.14%
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Ampio Pharmaceuticals, Inc. stock logo
AMPE
Ampio Pharmaceuticals
$0.18
$0.18
$0.00
▼
$0.64
$208K5.962,326 shsN/A
Carisma Therapeutics Inc. stock logo
CARM
Carisma Therapeutics
$0.00
-47.8%		$0.01
$0.00
▼
$0.56
$50K-9.0966,317 shs201 shs
Invitae Co. stock logo
NVTA
Invitae
$0.00
$0.00
$0.02
▼
$0.02
$80K1.5923.72 million shsN/A
Petros Pharmaceuticals, Inc. stock logo
PTPI
Petros Pharmaceuticals
$0.00
+22.9%		$0.00
$0.00
▼
$0.03
$134K1.88112,522 shs501,039 shs
7 Energy Stocks to Buy and Hold Forever Cover
7 Energy Stocks to Buy and Hold Forever

With the proliferation of data centers and electric vehicles, the electric grid will only get more strained. Download this report to learn how energy stocks can play a role in your portfolio as the global demand for energy continues to grow.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Ampio Pharmaceuticals, Inc. stock logo
AMPE
Ampio Pharmaceuticals
0.00%0.00%0.00%0.00%+6,681.48%
Carisma Therapeutics Inc. stock logo
CARM
Carisma Therapeutics
+4.55%+4.55%-45.24%+2,200.00%-99.04%
Invitae Co. stock logo
NVTA
Invitae
0.00%0.00%0.00%0.00%0.00%
Petros Pharmaceuticals, Inc. stock logo
PTPI
Petros Pharmaceuticals
-10.26%+2.94%-12.50%-42.62%-88.14%
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Ampio Pharmaceuticals, Inc. stock logo
AMPE
Ampio Pharmaceuticals
0.00
N/AN/AN/A
Carisma Therapeutics Inc. stock logo
CARM
Carisma Therapeutics
1.00
SellN/AN/A
Invitae Co. stock logo
NVTA
Invitae
0.00
N/AN/AN/A
Petros Pharmaceuticals, Inc. stock logo
PTPI
Petros Pharmaceuticals
0.00
N/AN/AN/A

Current Analyst Ratings Breakdown

CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Ampio Pharmaceuticals, Inc. stock logo
AMPE
Ampio Pharmaceuticals
N/AN/AN/AN/A$4.04 per shareN/A
Carisma Therapeutics Inc. stock logo
CARM
Carisma Therapeutics
$10.77M0.00N/AN/A($0.67) per share0.00
Invitae Co. stock logo
NVTA
Invitae
$481.58M0.00N/AN/A$0.42 per share0.00
Petros Pharmaceuticals, Inc. stock logo
PTPI
Petros Pharmaceuticals
$5.11M0.03N/AN/A$4.04 per share0.00
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Ampio Pharmaceuticals, Inc. stock logo
AMPE
Ampio Pharmaceuticals
-$8.63M-$11.01N/AN/AN/AN/AN/AN/AN/A
Carisma Therapeutics Inc. stock logo
CARM
Carisma Therapeutics
-$60.48M$0.730.00N/AN/A-254.28%N/A-192.17%8/21/2026 (Estimated)
Invitae Co. stock logo
NVTA
Invitae
-$3.11B-$5.38N/AN/AN/A-299.14%-6,100.71%-19.68%N/A
Petros Pharmaceuticals, Inc. stock logo
PTPI
Petros Pharmaceuticals
-$8.16M-$0.36N/AN/AN/AN/A-78.22%-23.50%N/A

Latest NVTA, AMPE, CARM, and PTPI Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
8/21/2026N/A
Carisma Therapeutics Inc. stock logo
CARM
Carisma Therapeutics
-$0.1139N/AN/AN/A$4.23 millionN/A
CompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive Growth
Ampio Pharmaceuticals, Inc. stock logo
AMPE
Ampio Pharmaceuticals
N/AN/AN/AN/AN/A
Carisma Therapeutics Inc. stock logo
CARM
Carisma Therapeutics
N/AN/AN/AN/AN/A
Invitae Co. stock logo
NVTA
Invitae
N/AN/AN/AN/AN/A
Petros Pharmaceuticals, Inc. stock logo
PTPI
Petros Pharmaceuticals
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Ampio Pharmaceuticals, Inc. stock logo
AMPE
Ampio Pharmaceuticals
N/AN/AN/A
Carisma Therapeutics Inc. stock logo
CARM
Carisma Therapeutics
N/A
0.48
0.48
Invitae Co. stock logo
NVTA
Invitae
N/A
2.39
2.25
Petros Pharmaceuticals, Inc. stock logo
PTPI
Petros Pharmaceuticals
1.58
0.85
0.74

Institutional Ownership

CompanyInstitutional Ownership
Ampio Pharmaceuticals, Inc. stock logo
AMPE
Ampio Pharmaceuticals
5.73%
Carisma Therapeutics Inc. stock logo
CARM
Carisma Therapeutics
44.27%
Invitae Co. stock logo
NVTA
Invitae
61.28%
Petros Pharmaceuticals, Inc. stock logo
PTPI
Petros Pharmaceuticals
12.34%

Insider Ownership

CompanyInsider Ownership
Ampio Pharmaceuticals, Inc. stock logo
AMPE
Ampio Pharmaceuticals
3.30%
Carisma Therapeutics Inc. stock logo
CARM
Carisma Therapeutics
6.90%
Invitae Co. stock logo
NVTA
Invitae
0.74%
Petros Pharmaceuticals, Inc. stock logo
PTPI
Petros Pharmaceuticals
12.25%
CompanyEmployeesShares OutstandingFree FloatOptionable
Ampio Pharmaceuticals, Inc. stock logo
AMPE
Ampio Pharmaceuticals
201.14 million1.10 millionNo Data
Carisma Therapeutics Inc. stock logo
CARM
Carisma Therapeutics
2041.85 million38.91 millionNo Data
Invitae Co. stock logo
NVTA
Invitae
1,700267.01 million284.37 millionNo Data
Petros Pharmaceuticals, Inc. stock logo
PTPI
Petros Pharmaceuticals
2031.16 million9.93 millionNot Optionable

Recent News About These Companies

Petros Pharmaceuticals Delays Annual 10-K Filing
March 31, 2026  |  tipranks.comhttps://www.tipranks.com/news/company-announcements/petros-pharmaceuticals-delays-annual-10-k-filing?utm_source=marketbeat.com&utm_medium=referral
Petros Pharmaceuticals grants significant RSUs to key leaders
January 3, 2026  |  msn.comhttps://www.msn.com/en-us/money/markets/petros-pharmaceuticals-grants-significant-rsus-to-key-leaders/ar-AA1TtTU6
Petros Pharmaceuticals to be Delisted from Nasdaq
November 7, 2025  |  msn.comhttps://www.msn.com/en-us/money/topstocks/petros-pharmaceuticals-to-be-delisted-from-nasdaq/ar-AA1Q1YLI
Petros Pharmaceuticals Inc (PTPI) - Investing.com
September 6, 2025  |  investing.comhttps://www.investing.com/equities/petros-pharmaceuticals-financial-summary
Petros Pharmaceuticals, Inc.: Petros Pharmaceuticals Announces Deconsolidation of Metuchen Pharmaceuticals Subsidiary, Strengthening its Balance Sheet and Improving the Company ...
June 26, 2025  |  finanznachrichten.dehttps://www.finanznachrichten.de/nachrichten-2025-06/65751359-petros-pharmaceuticals-inc-petros-pharmaceuticals-announces-deconsolidation-of-metuchen-pharmaceuticals-subsidiary-strengthening-its-balance-sheet-200.htm
Petros Pharmaceuticals Announces Deconsolidation of Metuchen Pharmaceuticals Subsidiary, Strengthening its Balance Sheet and Improving the Company's Equity Position | Morningstar
June 26, 2025  |  morningstar.comM
Petros Pharmaceuticals to deconsolidate subsidiary to improve finances
June 26, 2025  |  investing.comhttps://www.investing.com/news/company-news/petros-pharmaceuticals-to-deconsolidate-subsidiary-to-improve-finances-93CH-4110639
Petros Pharmaceuticals, Inc. (PTPI) - Yahoo Finance
June 26, 2025  |  finance.yahoo.comhttps://finance.yahoo.com/quote/PTPI/news/
Petros Pharmaceuticals Inc News (PTPI) - Investing.com
June 26, 2025  |  investing.comhttps://www.investing.com/equities/petros-pharmaceuticals-news
Petros Pharmaceuticals Announces Deconsolidation of Metuchen Pharmaceuticals Subsidiary, Strengthening its Balance Sheet and Improving the Company's Equity Position
June 25, 2025  |  accessnewswire.comA
Petros Pharmaceuticals to appeal Nasdaq delisting decision
May 23, 2025  |  uk.investing.comhttps://uk.investing.com/news/company-news/petros-pharmaceuticals-to-appeal-nasdaq-delisting-decision-93CH-4097289
Petros Pharmaceuticals Announces Transition from NASDAQ to OTC Markets
May 21, 2025  |  accessnewswire.comA
Petros Pharmaceuticals, Inc.: Petros Pharmaceuticals Partners with Innolitics, a Leading Software-as-a-Medical-Device Developer
May 20, 2025  |  finanznachrichten.dehttps://www.finanznachrichten.de/nachrichten-2025-05/65454967-petros-pharmaceuticals-inc-petros-pharmaceuticals-partners-with-innolitics-a-leading-software-as-a-medical-device-developer-200.htm
Petros Pharmaceuticals Partners with Innolitics, a Leading Software-as-a-Medical-Device Developer
May 20, 2025  |  accessnewswire.comA
Petros Pharmaceuticals Strengthens Partnership with Market Leading Big Data Provider Implementing Key Enhancements to its AI Platform
May 6, 2025  |  accessnewswire.comA
Petros Proprietary Technology Platform Aligns with April 15, 2025 President Trump Executive Order Advancing Rx-to-OTC Reclassification Reforms
April 29, 2025  |  accessnewswire.comA
Petros Pharmaceuticals, Inc.: Petros Pharmaceuticals to Partner with Renowned Big Data Provider to Enable Rx-to-OTC Switch Across Multiple Indications
March 20, 2025  |  finanznachrichten.dehttps://www.finanznachrichten.de/nachrichten-2025-03/64880782-petros-pharmaceuticals-inc-petros-pharmaceuticals-to-partner-with-renowned-big-data-provider-to-enable-rx-to-otc-switch-across-multiple-indications-200.htm
Petros Pharmaceuticals enters collaboration with big data, analytics firm
March 20, 2025  |  msn.comhttps://www.msn.com/en-us/technology/biotechnology/petros-pharmaceuticals-enters-collaboration-with-big-data-analytics-firm/ar-AA1Bkb77
Petros Pharmaceuticals to Partner with Renowned Big Data Provider to Enable Rx-to-OTC Switch Across Multiple Indications
March 20, 2025  |  accessnewswire.comA
Petros Pharmaceuticals, Inc.: Petros Pharmaceuticals' Proprietary Technology Demonstrates Positive Data in Pivotal Study
February 27, 2025  |  finanznachrichten.dehttps://www.finanznachrichten.de/nachrichten-2025-02/64653857-petros-pharmaceuticals-inc-petros-pharmaceuticals-proprietary-technology-demonstrates-positive-data-in-pivotal-study-200.htm

New MarketBeat Followers Over Time

Ampio Pharmaceuticals stock logo

Ampio Pharmaceuticals NYSE:AMPE

$0.18 0.00 (0.00%)
As of 08/20/2026

Ampio Pharmaceuticals, Inc., a biopharmaceutical company, develops therapies for the treatment of osteoarthritis of the knee (OAK) in the United States. It develops OA-201, a small molecule formulation for the treatment of OAK pain. The company is headquartered in Englewood, Colorado.

Carisma Therapeutics stock logo

Carisma Therapeutics NASDAQ:CARM

$0.0012 0.00 (-47.83%)
As of 02:10 PM Eastern

Carisma Therapeutics, Inc., a clinical-stage cell therapy company, focuses on discovering and developing immunotherapies to treat cancer and other serious diseases in the United States. The company's ex vivo CAR-M cell therapies include CT-0508, a CAR-macrophage, which is in Phase 1 clinical trial to treat solid tumors; CT-0525, a CAR-monocyte that is in Phase 1 clinical trial to treat solid tumors; and CT-1119, a mesothelin-targeted CAR-Monocyte that is in pre-clinical stage to treat patients with advanced mesothelin-positive solid tumors, including lung cancer, mesothelioma, pancreatic cancer, ovarian cancer, and others. It is also developing in vivo CAR-M cell therapies in collaboration with Moderna Therapeutics to address multiple cancer targets; and multiple assets for the potential treatment of diseases beyond oncology, including fibrosis and other immunologic and inflammatory diseases. The company was formerly known as CARMA Therapeutics Inc. and changed its name to Carisma Therapeutics, Inc. in May 2017. The company was founded in 2016 and is headquartered in Philadelphia, Pennsylvania.

Invitae stock logo

Invitae NYSE:NVTA

Invitae Corporation, a medical genetics company, that provides genetic information to improve healthcare of people in the United States, Canada, and internationally. The company offers genetic tests in various clinical areas, including hereditary cancer, precision oncology, women's health, rare diseases, and pharmacogenomics; digital health solutions; and health data services. It serves patients, healthcare providers, biopharma companies, and other partners. The company was formerly known as Locus Development, Inc. and changed its name to Invitae Corporation in 2012. Invitae Corporation was incorporated in 2010 and is headquartered in San Francisco, California.

Petros Pharmaceuticals stock logo

Petros Pharmaceuticals NASDAQ:PTPI

$0.0043 +0.00 (+22.86%)
As of 03:58 PM Eastern

Petros Pharmaceuticals, Inc., a pharmaceutical company, focuses on men's health therapeutics in the United States and internationally. It operates through two segments, Prescription Medications and Medical Devices. The company engages in the commercialization and development of Stendra, an PDE-5 inhibitor prescription medication for the treatment of erectile dysfunction (ED). It also develops and commercializes H100, a novel and patented topical formulation candidate for the treatment of acute Peyronie's disease. The company offers men's health products, including vacuum erection devices, penile injections, PreBoost, VenoSeal, and urinary tract infection tests for the treatment of erectile dysfunction. Petros Pharmaceuticals, Inc. is based in New York, New York.

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

Stock Lists
Low Priced Stocks
Stocks By Exchange
Latest Stock Ideas